Purple Biotech Announces Research Collaboration with the Icahn School of Medicine at Mount Sinai for CAPTN-3 Tri-Specific Antibody Platform
Collaboration to explore the immunoregulation of NK and T cells within the tumor microenvironment (TME) by CAPTN-3, with the ...
Morningstar11d
Purple Biotech Announces Research Collaboration with the Icahn School of Medicine at Mount Sinai for CAPTN-3 Tri-Specific Antibody Platform
Purple Biotech Ltd. (NASDAQ/TASE ... The Company is advancing CAPTN-3, a preclinical platform of conditionally-activated tri-specific antibody that engages both T cells and NK cells to induce ...
Business Insider11d
Purple Biotech Announces Research Collaboration with the Icahn School of Medicine at Mount Sinai for CAPTN-3 Tri-Specific Antibody Platform
About Purple Biotech Purple Biotech Ltd. (NASDAQ/TASE ... a preclinical platform of conditionally-activated tri-specific antibody that engages both T cells and NK cells to induce a strong ...
Purple Biotech announces research collaboration with Icahn School of Medicine
Purple Biotech (PPBT) announced that it has entered into a Research Collaboration Agreement with the Icahn School of Medicine at Mount Sinai in ...
manilatimes11d
Purple Biotech Announces Research Collaboration with the Icahn School of Medicine at Mount Sinai for CAPTN-3 Tri-Specific Antibody Platform
Purple Biotech Ltd. (NASDAQ/TASE: PPBT ... The Company is advancing CAPTN-3, a preclinical platform of conditionally-activated tri-specific antibody that engages both T cells and NK cells to induce a ...
ENDPOINTS NEWS11d
Ex­clu­sive: Ger­man biotech de­clares Phase 2 win for non-opi­oid drug for neu­ro­path­ic pain
Algiax Pharmaceuticals’ non-opioid candidate has achieved “clinically meaningful” pain reduction in a mid-stage trial of ...
ENDPOINTS NEWS3h
BioN­Tech vets raise $90M Se­ries A for bis­pe­cif­ic I&I start­up
Bambusa Therapeutics raises $90M Series A for bispecific antibodies, led by RA Capital. Founded by BioNTech veterans, plans ...